PURE Bioscience Board Appoints Paul V. Maier to Board of Directors
SAN DIEGO,
Michael L. Krall, President/CEO and Chairman of PURE Bioscience, commented, “Paul brings to PURE Bioscience more than 30 years of executive experience not only in pharmaceutical and biotechnology companies but also in consumer products companies. We expect to benefit from his expertise in strategic planning within rapid growth environments and from his extensive financial expertise, including Sarbanes-Oxley compliance management and audit and compensation committee experience. Paul will be instrumental in the formation and leadership of those committees for PURE Bioscience.”
Paul V. Maier, stated, “Pure Bioscience is well positioned to capitalize on its unique proprietary antimicrobial technology. I look forward to working with PURE Bioscience’s board and senior management to support its exciting strategic growth and commercialization opportunities.”
Mr. Maier is the former Chief Financial Officer of Ligand Pharmaceutical Incorporated. During his 14 year tenure, he played an integral role in the Company’s growth. Prior to his association with Ligand, Mr. Maier served as Vice President, Finance at DFS West, a division of DFS Group, L.P., and a private multinational retailer. Previously, Mr. Maier was employed by ICN Pharmaceuticals, Inc., a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as in SPI Pharmaceuticals, Inc., a publicly held subsidiary of ICN Pharmaceuticals Group. Mr. Maier is a member of the board of directors of International Stem Cell Corporation. Mr. Maier received an M.B.A. from Harvard Graduate School of Business and a B.S. from
Mr. Maier serves on the PURE Bioscience Board as an independent director. Mr. Maier is not, and has not been for the past three years, employed by the Company or by any parent or subsidiary of the Company and has not accepted any payments from the Company or any parent or subsidiary of the Company during the current or any of the past three fiscal years. No family relationships exist between Mr. Maier and PURE Bioscience, its directors or officers.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.